Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: Study protocol for a randomized controlled trial

Trials

Volumn 18, Issue 1, 2017, Pages

  Bellingan, Geoff ^a   Brealey, David ^a   Mancebo, Jordi ^b   Mercat, Alain ^c   Patroniti, Nicolò ^d   Pettilä, Ville ^e   Quintel, Michael ^f   Vincent, Jean Louis ^g   Maksimow, Mikael ^h   Jalkanen, Markku ^h   Piippo, Ilse ^h   Ranieri, V Marco ⁱ  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d SAN GERARDO HOSPITAL   (Italy)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g ERASME HOSPITAL   (Belgium)

^h Faron Pharmaceuticals Oy   (Finland)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ARDS; CD73; Interferon; Vascular leakage

Indexed keywords

BETA1A INTERFERON; FP 1201 LYO; MYXOVIRUS RESISTANCE PROTEIN A; PLACEBO;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFORMED CONSENT; INTENSIVE CARE UNIT; MORTALITY; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; UNSPECIFIED SIDE EFFECT; CLINICAL PROTOCOL; CLINICAL TRIAL; DIET THERAPY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; EUROPE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MALE; METHODOLOGY; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; CAUSE OF DEATH; CLINICAL PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INTERFERON BETA-1A; LENGTH OF STAY; MALE; RESEARCH DESIGN; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85033781066     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-017-2234-7     Document Type: Article

References (22)

1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526-33.
2. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 2008;133:1120-7.
3. Cochi SE, Kempker JA, Annangi S, Kramer MR, Martin GS. Mortality trends of acute respiratory distress syndrome in the United States from 1999-2013. Ann Am Thorac Soc. 2016;13:1742-51.
4. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, et al. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med. 2009;179:220-7.
5. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788-800.
6. Rossi C, Simini B, Brazzi L, Rossi G, Radrizzani D, Iapichino G, et al. Variable costs of ICU patients: a multicenter prospective study. Intensive Care Med. 2006;32:545-52.
7. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293-304.
8. Hopkins RO, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme Jr JF. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2005;171:340-7.
9. Cheung AM, Tansey CM, Tomlinson G, Diaz-Granados N, Matte A, Barr A, et al. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2006;174:538-44.
10. Umapathy NS, Fan Z, Zemskov EA, Alieva IB, Black SM, Verin AD. Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement. Vascul Pharmacol. 2010;52:199-206.
11. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, et al. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 2004;200:1395-405.
12. Kiss J, Yegutkin GG, Koskinen K, Savunen T, Jalkanen S, Salmi M. IFN-beta protects from vascular leakage via up-regulation of CD73. Eur J Immunol. 2007;37:3334-8.
13. Bellingan G, Maksimow M, Howell DC, Stotz M, Beale R, Beatty M, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med. 2014;2:98-107.
14. Eckle T, Fullbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, et al. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol. 2007;178:8127-37.
15. Aeffner F, Woods PS, Davis IC. Activation of A1-adenosine receptors promotes leukocyte recruitment to the lung and attenuates acute lung injury in mice infected with influenza A/WSN/33 (H1N1) virus. J Virol. 2014;88:10214-27.
16. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-24.
17. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-4.
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-29.
19. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-10.
20. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-8.
21. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, de Boisblanc B, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564-75.
22. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18:1341-54.